Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2006 2
2007 1
2008 1
2009 1
2010 2
2011 2
2012 1
2014 6
2015 4
2016 8
2017 3
2018 3
2019 1
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A, Lupatsch JE, Schwenkglenks M, Panje CM, Matter-Walstra K, Espeli V, Dedes KJ, Siano M; Swiss Group of Clinical Cancer Research (SAKK). Hirschmann A, et al. Among authors: matter walstra k. Oral Oncol. 2018 Dec;87:104-110. doi: 10.1016/j.oraloncology.2018.10.032. Epub 2018 Oct 30. Oral Oncol. 2018. PMID: 30527224
A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).
Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK). Panje CM, et al. Among authors: matter walstra k. Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10. Radiother Oncol. 2018. PMID: 30104008 Clinical Trial.
End-of-life costs of medical care for advanced stage cancer patients.
Kovacević A, Dragojević-Simić V, Rancić N, Jurisević M, Gutzwiller FS, Matter-Walstra K, Jakovljević M. Kovacević A, et al. Among authors: matter walstra k. Vojnosanit Pregl. 2015 Apr;72(4):334-41. doi: 10.2298/vsp1504334k. Vojnosanit Pregl. 2015. PMID: 26040179
Trastuzumab beyond progression: a cost-utility analysis.
Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Matter-Walstra KW, et al. Ann Oncol. 2010 Nov;21(11):2161-2168. doi: 10.1093/annonc/mdq250. Epub 2010 May 5. Ann Oncol. 2010. PMID: 20444849 Free article.
34 results